Aligos Therapeutics Inc Cash Flow Conversion Efficiency
Aligos Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, Aligos Therapeutics Inc (ALGS) has a cash flow conversion efficiency ratio of -0.728x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-23.13 Million) by net assets ($31.79 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Aligos Therapeutics Inc (2018–2025)
Cash flow conversion efficiency of Aligos Therapeutics Inc from 2018 to 2025. This chart illustrates how Aligos Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View ALGS share price today for real-time trading data and today's change.
Aligos Therapeutics Inc Cash Flow Conversion Ratio Explained
Aligos Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Aligos Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Aligos Therapeutics Inc ranked by their cash flow conversion efficiency. Also see ALGS company net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Damartex
PA:ALDAR
|
0.473x |
|
PESTECH International Bhd
KLSE:5219
|
-0.161x |
|
Archtis Ltd
AU:AR9
|
-0.252x |
|
Latrobe Magnesium Limited
F:L2Q
|
0.064x |
|
EDM Resources Inc
V:EDM
|
-0.067x |
|
Ribbon Acquisition Corp Class A Ordinary Shares
NASDAQ:RIBB
|
0.000x |
|
Pioneer Motor Public Company Limited
BK:PIMO
|
0.043x |
|
Sung Gang Asset Management Ltd
TWO:6240
|
0.016x |
Annual Cash Flow Conversion Efficiency for Aligos Therapeutics Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Aligos Therapeutics Inc from 2018 to 2025. Review ALGS free cash flow debt coverage to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $53.55 Million | $-82.50 Million | -1.541x | -155.29% |
| 2024-12-31 | $-28.97 Million | $-80.74 Million | 2.787x | +424.84% |
| 2023-12-31 | $92.08 Million | $-79.00 Million | -0.858x | -12.28% |
| 2022-12-31 | $103.90 Million | $-79.39 Million | -0.764x | -22.04% |
| 2021-12-31 | $184.73 Million | $-115.66 Million | -0.626x | -85.51% |
| 2020-12-31 | $220.04 Million | $-74.26 Million | -0.337x | -146.83% |
| 2019-12-31 | $-64.89 Million | $-46.77 Million | 0.721x | +63.80% |
| 2018-12-31 | $-13.75 Million | $-6.05 Million | 0.440x | -- |
About Aligos Therapeutics Inc
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity. The company also develops pevifosc… Read more